Trial Profile

A randomized open label pivotal trial of SM-88 in third-line metastatic advanced pancreatic cancer patients

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Racemetyrosine (Primary) ; Methoxsalen; Phenytoin; Sirolimus
Indications Pancreatic cancer
Focus Registrational; Therapeutic Use
Sponsors Tyme Technologies

Most Recent Events

21 Aug 2020 According to a Tyme Technologies media release, information about this trial will be presented at 2020 Cross-Border Healthcare Webinar Series.
04 Nov 2019 Status changed from planning to not yet recruiting, according to a Tyme Technologies media release.
04 Nov 2019 According to a Tyme Technologies media release, the company has received the Central Institutional Review Board approval and enrollment is expected to be underway in fourth quarter of 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com